Remove Clinical Trials Remove Data Remove Safety Remove Sleep
article thumbnail

First Ever Clinical Trial for Cannabis Migraine Treatment is Underway

Veriheal

However, there has not been a clinical trial assessing the efficacy of cannabis for migraines, at least not until now. Science Alert has announced that the first clinical trial for cannabis as a migraine treatment is underway. The First Clinical Trial for Migraines and Cannabis.

article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Study On CBD And Sleep Shows Promising Results

Miss Marijuana

A new study concludes that PlusCBD Oil supplements can help improve sleep, support reduction in appetite and help enhance quality of life in humans. . Did you know sleep deficiency is a pretty common health issue in the United States? By: Madeleine Balestrier. The Center for Applied Health Sciences’s (CAHS) main goal for this study: .

Sleep 72
article thumbnail

cbdMD Therapeutics Releases Research Plan

Cannabis Law Report

The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids.

article thumbnail

Study Examines “Encouraging” Evidence on Medical Marijuana Treating Psychiatric Disorders

The Joint Blog

.” For this study, “The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted.” Preliminary research findings indicate no benefit for depression from high delta-9 tetrahydrocannabinol (THC) therapeutics, or for CBD in mania. .”

article thumbnail

Clinical Trial Explores CBD’s Influence on Cannabis Safety

Veriheal

A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . About the Study Into CBD’s Influence on Cannabis Safety.

article thumbnail

IGC Reports Financial Results for the September 30, 2021 Quarter

Cannabis Law Report

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease. March 31, 2021. ($). .